Source Precision Medicine, Inc. d/b/a Source MDx Announces Foundational Patents Will Be Offered for Sale on April 29, 2011

WELLESLEY HILLS, Massachusetts, March 21, 2011 - Joseph F. Finn, Jr., C.P.A. ("Finn") Assignee for the Benefit of
Creditors of Source Precision Medicine, Inc. d/b/a/ Source MDx ("Source MDx")
announced that the foundational patents of Source MDx will be offered for
sale on April 29, 2011.

Source MDx holds a broad-based, array of patents that cover technical
aspects of RNA transcript measurement, concepts surrounding normal ranges in
healthy human subjects ("normals") and statistical methods generating
multi-gene models for the discrimination of normals versus disease. Key
patents comprise the foundation of Source MDx's intellectual property
portfolio. These include:

A. Systems and Methods for Characterizing a Biological Condition or Agent
using Precision Gene Expression (#6,692,916 issued 02.17.04)

B. Identification, Monitoring and Treatment of Disease and
Characterization of Biological Condition Using Gene Expression Profiles
(#6,940,439 issued 11.01.05)

C. Identification, Monitoring and Treatment of Disease and
Characterization of Biological Condition Using Gene Expression Profiles
(#6,964,850 pending)

Persons interested in bidding must sign a Confidentiality Disclosure
Agreement ("CDA") obtained from Finn's office - jffinnjr@finnwarnkegayton or
+1-781-237-8840. They will then receive a bid package.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm Finn,
Warnke & Gayton LLP of Wellesley Hills, Massachusetts
(www.finnwarnkegayton.com). He works primarily in the area of
management consulting for distressed enterprises, bankruptcy accounting and
related matters, such as Assignee for the Benefit of Creditors and
Liquidating Agent for corporations. He has been involved in a number of loan
workouts and bankruptcy cases for thirty-six (36) years. His most recent
Assignments for the Benefit of Creditors in the biotech field include
Spherics, Inc., ActivBioics, Inc. Prospect Therapeutics, Inc. and Epix
Pharmaceuticals, Inc.

For further information, please contact Joseph F. Finn, Jr., C.P.A. at
+1-781-237-8840 or jffinnjr@finnwarnkegatyon.com

Joseph F. Finn, Jr., C.P.A., +1-781-237-8840, jffinnjr at finnwarnkegatyon.com